A new arylpyrazolopyrimidinone derivative (33) was reported to exert a dual PDE5 and androgen receptor (AR) inhibitory activity that showed a significant cytotoxic effect on breast cancer cell lines [129]. This evidence concerns the gene PDE5A and breast cancer.